OncoHost has entered a clinical trial partnership with Roswell Park Comprehensive Cancer Center in the US to evaluate immunotherapy resistance in the PROPHETIC study.

Under the partnership, Roswell Park has opened a clinical site in Buffalo, New York for the study.

Go deeper with GlobalData

Data Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

The trial site will leverage PROphet, a precision oncology platform of OncoHost, to carry out proteomic assessments on subjects treated with immunotherapy to predict their response to the treatment.

The subjects will comprise patients with malignant melanoma, small cell lung cancer (SCLC) and non-small cell lung cancer (NSCLC).

In the host response assessment of individuals with late-stage lung cancer, the platform had demonstrated robust accuracy. 

PROphet merges proteomic analysis with artificial intelligence (AI) for predicting the response of the patients to immunotherapy and detecting resistance linked with the processes.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

According to latest findings from the ongoing PROPHETIC study through assessment of a blood test before treatment, PROphet could forecast response in NSCLC patients with increased precision at three, six months and one year.

Furthermore, it could identify prospective drug targets, which aids in developing new treatment strategies and offer clinicians with possible combinations to overcome resistance to therapies.

So far, OncoHost has launched over 35 trial sites across the globe, extending the reach of the study to new regions and offering a wider body of evidence-based research before the launch of PROphet in the US this year.

OncoHost CEO Dr Ofer Sharon said: “With Roswell Park joining our multicentre trial we can now expand recruitment, further developing our research base and improving on our current technology capabilities.

“We anticipate strong results from this study, which will eventually help us provide a premier tool for oncologists and physicians in the fight against cancer.”